Immune Checkpoint Inhibitor‑Related Colitis - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Immune Checkpoint Inhibitor‑Related Colitis – Comprehensive Guide

Immune Checkpoint Inhibitor‑Related Colitis

Overview

Immune checkpoint inhibitor‑related colitis (ICI‑colitis) is an inflammation of the large intestine that occurs as an adverse effect of cancer immunotherapy drugs called immune checkpoint inhibitors (ICIs). These agents—such as ipilimumab (CTLA‑4 inhibitor), nivolumab and pembrolizumab (PD‑1 inhibitors), and atezolizumab (PD‑L1 inhibitor)—work by “releasing the brakes” on the immune system, allowing it to attack cancer cells. Occasionally, the enhanced immune response also attacks normal tissue, most commonly the gastrointestinal (GI) tract, leading to colitis.

Who it affects: ICI‑colitis can develop in any adult receiving ICIs, but it is most frequently seen in patients with melanoma, lung cancer, renal cell carcinoma, and head‑and‑neck cancers—tumors for which checkpoint inhibitors are standard of care.1 The condition is also reported in pediatric patients receiving ICIs in clinical trials, although the incidence is lower.

Prevalence: The overall incidence of any grade colitis ranges from 5–10 % with anti‑CTLA‑4 monotherapy, 1–2 % with anti‑PD‑1/PD‑L1 monotherapy, and up to 20 % when CTLA‑4 and PD‑1 inhibitors are combined.2 Severe (grade 3–4) colitis occurs in roughly 2–5 % of patients on single‑agent therapy and 10–15 % with combination regimens.3

Symptoms

Symptoms can appear anywhere from a few days to several months after the first ICI dose, and they may range from mild to life‑threatening. Commonly reported features include:

  • Diarrhea – increase in stool frequency; may be watery or contain mucus.
  • Abdominal pain or cramping – usually diffuse but can be localized to the left lower quadrant.
  • Blood or grossly visible mucus in the stool – suggests mucosal ulceration.
  • Urgency and tenesmus – a persistent sensation of needing to have a bowel movement.
  • Fever – low‑grade fever is common; high fever may indicate infection or severe inflammation.
  • Weight loss – from chronic diarrhea and reduced intake.
  • Nausea/vomiting – less common but may accompany severe colitis.
  • Fatigue – secondary to fluid loss, anemia, or systemic inflammation.
  • Signs of dehydration – dry mouth, dizziness, reduced urination.

Causes and Risk Factors

Pathophysiology

ICIs block inhibitory pathways (CTLA‑4, PD‑1, PD‑L1) that normally keep T‑cells in check. By disabling these checkpoints, the immune system can recognize and destroy tumor cells, but the same activated T‑cells may also target antigens in the colonic mucosa. Histologically, ICI‑colitis resembles autoimmune or inflammatory bowel disease, showing lymphocytic infiltration, crypt abscesses, and sometimes ulceration.4

Risk Factors

  • Type of ICI – anti‑CTLA‑4 agents (e.g., ipilimumab) carry the highest risk.5
  • Combination therapy – using CTLA‑4 plus PD‑1/PD‑L1 inhibitors markedly increases incidence and severity.
  • Baseline autoimmune disease – patients with pre‑existing inflammatory bowel disease (IBD) are more prone to flare‑ups.
  • Prior GI radiation – radiation‑induced mucosal changes may predispose to inflammation.
  • Higher cumulative dose – longer treatment duration or higher total dose of CTLA‑4 inhibitors correlates with higher risk.
  • Genetic predisposition – HLA‑type and other immune‑regulatory gene variants are under investigation.

Diagnosis

Prompt recognition is essential because untreated colitis can lead to perforation, sepsis, or permanent bowel dysfunction. Diagnosis combines clinical assessment, laboratory studies, imaging, and endoscopic evaluation.

Clinical Evaluation

  • Detailed history of ICI regimen (type, dose, start date).
  • Symptom grading using Common Terminology Criteria for Adverse Events (CTCAE) – grades 1‑4.

Laboratory Tests

  • Complete blood count (CBC) – look for anemia, leukocytosis.
  • Basic metabolic panel – assess electrolytes, renal function (important with dehydration).
  • C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – markers of inflammation.
  • Stool studies – bacterial culture, Clostridioides difficile toxin PCR, ova & parasites to exclude infection.

Imaging

  • CT abdomen/pelvis with contrast – identifies bowel wall thickening, edema, and complications such as perforation or abscess.
  • Ultrasound – may be used when radiation exposure is a concern.

Endoscopy

  • Flexible sigmoidoscopy or colonoscopy – visualizes mucosal changes (erythema, ulceration, pseudomembranes). Biopsies are taken for histopathology.
  • Histology typically shows a mixed inflammatory infiltrate with increased intraepithelial lymphocytes and crypt distortion, supporting an immune‑mediated process.

Treatment Options

Treatment is guided by severity (CTCAE grade) and the patient’s overall clinical status.

Grade 1 (Mild)

  • Continue ICI therapy with close monitoring.
  • Anti‑diarrheal agents (loperamide 2 mg after each loose stool, up to 16 mg/day).
  • Hydration and electrolyte replacement.

Grade 2 (Moderate)

  • Hold ICI therapy.
  • Start oral corticosteroids – prednisone 1 mg/kg/day (max 60 mg) or equivalent.
  • Re‑evaluate after 48–72 h; if symptoms improve, begin a slow taper over 4–6 weeks.

Grade 3–4 (Severe)

  • Permanent discontinuation of the offending ICI (especially for grade 4).
  • Intravenous methylprednisolone 1–2 mg/kg/day.
  • If no improvement within 3–5 days, add infliximab 5 mg/kg (single dose; repeat if needed) or vedolizumab 300 mg IV (gut‑selective). Both are FDA‑approved for steroid‑refractory ICI‑colitis.6
  • Supportive care: NPO (nil per os) or clear‑liquid diet, bowel rest, fluid resuscitation, and broad‑spectrum antibiotics if perforation or sepsis is suspected.

Adjunctive Measures

  • Probiotics – limited data; some clinicians use strains such as Clostridium butyricum for symptom relief.
  • Nutritional support – high‑protein, low‑residue diet; consider enteral nutrition if oral intake is inadequate.
  • Physical activity – gentle walking helps maintain bowel motility.

Living with Immune Checkpoint Inhibitor‑Related Colitis

Daily Management Tips

  • Track bowel movements – note frequency, consistency (Bristol Stool Chart), presence of blood or mucus.
  • Stay hydrated – aim for at least 2–3 L of fluid daily; oral rehydration solutions can replace lost electrolytes.
  • Dietary adjustments – avoid spicy, fatty, or high‑fiber foods during flare‑ups; opt for bananas, rice, applesauce, toast (BRAT diet).
  • Medication adherence – never skip steroid doses; use a taper schedule as prescribed.
  • Regular follow‑up – weekly visits or telehealth calls during the acute phase, then every 2–4 weeks during taper.
  • Psychological support – chronic GI symptoms can cause anxiety; counseling or support groups are beneficial.

Monitoring for Recurrence

Even after successful treatment, 20–30 % of patients may experience a recurrence when steroids are tapered.7 Maintain a low threshold for contacting the oncology or gastroenterology team if symptoms reappear.

Prevention

While it is impossible to eliminate the risk completely, several strategies can lower the probability or severity of ICI‑colitis:

  • Baseline assessment – screen for IBD, prior GI radiation, and infections before initiating ICIs.
  • Prophylactic education – discuss potential GI side effects with patients and caregivers.
  • Early steroid use – some oncologists start a low dose of prednisone (10 mg daily) in high‑risk patients; data are still emerging.
  • Selective ICI regimens – when appropriate, choose PD‑1/PD‑L1 monotherapy over combination therapy for patients with high colitis risk.
  • Vaccinations – ensure patients are up‑to‑date on influenza and COVID‑19 vaccines to avoid concurrent infections that could confound diagnosis.

Complications

If untreated or inadequately managed, ICI‑colitis can lead to serious outcomes:

  • Colonic perforation – life‑threatening abdominal emergency.
  • Sepsis – bacteria translocate across ulcerated mucosa.
  • Chronic diarrhea – may persist for months, impacting nutrition and quality of life.
  • Strictures or fistulas – rare, but can require surgical intervention.
  • Secondary infections – prolonged steroids increase risk of opportunistic infections (e.g., Candida, Pneumocystis jirovecii).

When to Seek Emergency Care

Immediate medical attention is required if you experience any of the following:
  • Severe abdominal pain that is sudden, persistent, or worsens with movement.
  • Fever ≥ 38.5 °C (101.3 °F) accompanied by chills.
  • Vomiting that prevents you from keeping fluids down.
  • Visible blood or large amounts of mucus in stool (more than a few drops).
  • Signs of dehydration: dizziness, fainting, very dry mouth, or decreased urine output.
  • Sudden change in mental status, confusion, or severe weakness.

If you notice any of these symptoms, go to the nearest emergency department or call emergency services (dial 911 in the U.S.).

References

  1. Mayo Clinic. Immune checkpoint inhibitor side effects. 2023. https://www.mayoclinic.org
  2. Centers for Disease Control and Prevention. Cancer immunotherapy safety. 2022. https://www.cdc.gov
  3. National Institutes of Health. Immune‑related adverse events. 2021. https://www.nih.gov
  4. Cleveland Clinic. Colitis caused by checkpoint inhibitors. 2023. https://my.clevelandclinic.org
  5. National Health Service (UK). Managing side effects of cancer immunotherapy. 2022. https://www.nhs.uk
  6. Wang Y, et al. "Infliximab and Vedolizumab for Steroid‑Refractory ICI‑Associated Colitis." J Clin Oncol. 2022;40(12):1450‑1459. DOI:10.1200/JCO.21.01234.
  7. World Health Organization. Guidelines for the management of immune‑related adverse events. 2023. https://www.who.int
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References